151 material Form 8-K filings that 136 companies we cover made with the SEC in February 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MYR Group reported fourth-quarter and full-year 2023 results on February 28, 2024, with full-year contract revenues of $3.64 billion, up 21.1 percent, and full-year net income of $91.0 million, or $5.40 per diluted share, up from $4.91 a year earlier. Fourth-quarter net income was $24.0 million, or $1.43 per diluted share, down from $1.46 in the same quarter of 2022, while fourth-quarter revenue rose 16.2 percent. The company's backlog was $2.51 billion at December 31, 2023.
Q4 2023 revenue was $1.00 billion, up $140.2 million or 16.2 percent from Q4 2022
Full-year 2023 net income was $91.0 million, or $5.40 per diluted share, versus $83.4 million, or $4.91 per diluted share, in 2022
Full-year gross margin fell to 10.0 percent from 11.4 percent, while Q4 net income declined 2.2 percent
Backlog was $2.51 billion at December 31, 2023, compared with $2.62 billion at September 30, 2023
EMCOR reported record fourth-quarter and full-year 2023 revenue and diluted earnings per share, and its board approved a quarterly dividend increase to $0.25 per share from $0.18. The company also guided 2024 revenue to $13.5 billion-$14.0 billion and diluted EPS to $14.00-$15.00, above 2023 levels.
Q4 2023 revenue $3.44 billion, up 16.6%; Q4 diluted EPS $4.47 versus $2.63 a year earlier
Full-year 2023 revenue $12.58 billion, up 13.6%; diluted EPS $13.31 versus $8.10 in 2022
TG Therapeutics reported fourth quarter and full year 2023 results, furnished as Exhibit 99.1 to a Form 8-K. Full-year total revenue was $233.7 million, including a $140.0 million one-time payment from Neuraxpharm, and the company swung to net income of $12.7 million from a $198.3 million net loss in 2022. The company also set a 2024 BRIUMVI U.S. net product revenue target of $220 million to $260 million, giving shareholders a benchmark for future results.
Q4 2023 total revenue was $44.0 million versus $80 thousand in Q4 2022; Q4 net loss narrowed to $14.4 million from $53.0 million.
Full-year 2023 BRIUMVI U.S. net product revenue was $88.8 million; license, milestone and other revenue was $141.7 million, mainly from the $140.0 million Neuraxpharm payment received in July 2023.
2024 targets: BRIUMVI U.S. net product revenue of approximately $220 million to $260 million and total operating expense of approximately $250 million.
Year-end 2023 cash, cash equivalents and investment securities were $217.5 million.
Warby Parker reported fourth quarter and full year 2023 results on February 28, 2024. Full year net revenue rose 12.0% to $669.8 million, and the GAAP net loss narrowed to $63.2 million from $110.4 million in 2022. The company also guided to 2024 net revenue of $748 million to $758 million, about 12% to 13% growth, and adjusted EBITDA of about $67 million at the revenue midpoint.
Full year 2023 net revenue increased 12.0% to $669.8 million; fourth quarter net revenue rose 10.5% to $161.9 million.
Full year GAAP net loss was $63.2 million, versus $110.4 million in 2022; fourth quarter GAAP net loss was $19.0 million.
2024 outlook: net revenue of $748 million to $758 million and adjusted EBITDA of $67 million at the revenue midpoint, with 40 new store openings planned.
Gross margin fell to 54.5% from 57.0% in 2022, which the company attributed mainly to growth in lower-margin contact lenses.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.